A study from Wake Forest Institute for Regenerative Medicine, Winston-Salem, N.C., offers hope for end-stage kidney disease in cats.
Chronic tubulointerstitial fibrosis is a common final pathway leading to end stage kidney disease in cats and has no effective treatment. The use of cell-specific molecules to treat kidney fibrosis may be a promising approach.
Researchers looked at the effects of intra-renal chemokine CXCL12 injection in a pre-clinical cat model of unilateral ischemia/reperfusion (I/R)-induced kidney fibrosis and the safety/feasibility of these injections in cats that might have early chronic kidney disease.
“The goal of this study was to test the safety, feasibility, and efficacy of ultrasound-guided intra-renal CXCL12 injection in cats with chronic kidney fibrosis, first in a preclinical cat model, and then in a pilot study in cats that may have early kidney disease,” according to a release from EurekAlert, from the American Association for the Advancement of Science.
The researchers found that intra-renal injection of CXCL12 may prove to be an effective treatment for kidney fibrosis in cats with CKD. Additional mechanistic and clinical evaluations are needed.n
Front. Vet. Sci., 04 March 2021 | https://doi.org/10.3389/fvets.2021.646087
